FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.05-4829fje.
This Article
Right arrow Summary
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
fj.05-4829fjev1
20/8/1185    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilic, E.
Right arrow Articles by Hermann, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilic, E.
Right arrow Articles by Hermann, D. M.
(The FASEB Journal. 2006;20:1185-1187.)
© 2006 FASEB

The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF’s neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia

Ertugrul Kilic*,1, Ülkan Kilic*, Yaoming Wang*,2, Claudio L. Bassetti*, Hugo H. Marti{dagger} and Dirk M. Hermann*

* Department of Neurology, University Hospital Zurich (USZ), Zurich, Switzerland; and

{dagger} Institute of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany

1Correspondence: Department of Neurology, University Hospital Zurich, Frauenklinikstr. 26, CH-8091 Zurich, Switzerland. E-mail: ertugrul.kilic{at}usz.ch

ABSTRACT

Based on its trophic influence on neurons and vascular cells, vascular endothelial growth factor (VEGF) is a promising candidate for stroke treatment. VEGF’s survival-promoting effects are purchased at the expense of an increased blood brain barrier permeability, which potentially compromises tissue survival. The mechanisms via which VEGF protects the brain against ischemia remained unknown. We examined signaling pathways underlying VEGF’s neuroprotective activity in our transgenic mouse line, which expresses human VEGF165 under a neuron-specific enolase (NSE) promoter. We show that VEGF receptor-2 (Flk-1) is expressed on ischemic neurons and astrocytes and is activated by VEGF. Following 90-min episodes of middle cerebral artery occlusion, VEGF increased phosphorylated (but not total) Akt and ERK-1/-2 and reduced phosphorylated mitogen activated protein kinase/p38 and c-Jun NH2-terminal kinase (JNK)-1/-2 levels, at the same time decreasing inducible NO synthase expression in ischemic neurons. Inhibition of Akt with Wortmannin reversed VEGF’s neuroprotective properties, diminished brain swelling, and restored the vascular permeability induced by VEGF to below levels in WT animals. The aggravation of brain injury by Wortmannin was associated with the restitution of p38, but not of JNK-1/-2, ERK-1/-2, or inducible NOS (iNOS). Our data demonstrate that VEGF mediates both neuroprotection and blood brain barrier permeability via the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Based on our observation that VEGF neuroprotection and vascular leakage depend on PI3K/Akt, which is putatively regulated by VEGF receptor-2, we predict that it may not easily be possible to make use of VEGF’s neuroprotective function without accepting its unfavorable consequence, the increased vascular permeability.—Kilic, E., Kilic, Ü., Wang, Y., Bassetti, C. L., Marti, H. H., Hermann, D. M. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF’s neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia.




This article has been cited by other articles:


Home page
Therapeutic Advances in Neurological DisordersHome page
D. M. Hermann
Review: Future perspectives for brain pharmacotherapies: implications of drug transport processes at the blood--brain barrier
Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 167 - 179.
[Abstract] [PDF]


Home page
StrokeHome page
D. M. Hermann and E. Kilic
Therapeutic Potential and Possible Risks of Pleiotropic Growth Factors in Ischemic Stroke
Stroke, November 1, 2008; 39(11): e182 - e182.
[Full Text] [PDF]


Home page
BrainHome page
E. Kilic, A. Spudich, U. Kilic, K. M. Rentsch, R. Vig, C. M. Matter, H. Wunderli-Allenspach, J.-M. Fritschy, C. L. Bassetti, and D. M. Hermann
ABCC1: a gateway for pharmacological compounds to the ischaemic brain
Brain, October 1, 2008; 131(10): 2679 - 2689.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. An, C. Zhang, R. Polavarapu, X. Zhang, X. Zhang, and M. Yepes
Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain
Blood, October 1, 2008; 112(7): 2787 - 2794.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K. S. Lee, S. J. Park, S. R. Kim, K. H. Min, K. Y. Lee, Y. H. Choe, S. H. Hong, Y. R. Lee, J. S. Kim, S. J. Hong, et al.
Inhibition of VEGF blocks TGF-{beta}1 production through a PI3K/Akt signalling pathway
Eur. Respir. J., March 1, 2008; 31(3): 523 - 531.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
W. Feng, R. E. Brown, C. D. Trung, W. Li, L. Wang, T. Khoury, S. Alrawi, J. Yao, K. Xia, and D. Tan
Morphoproteomic Profile of mTOR, Ras/Raf Kinase/ERK, and NF-{kappa}B Pathways in Human Gastric Adenocarcinoma
Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 195 - 209.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
V. Rigau, M. Morin, M.-C. Rousset, F. de Bock, A. Lebrun, P. Coubes, M.-C. Picot, M. Baldy-Moulinier, J. Bockaert, A. Crespel, et al.
Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy
Brain, July 1, 2007; 130(7): 1942 - 1956.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The Federation of American Societies for Experimental Biology.